Besides imatinib and dasatinib, in recent years several new-generation BCR::ABL1-directed TKIs have been developed primarily for patients with chronic myeloid leukemia (CML), including nilotinib, bosutinib, ponatinib, and olverembatinib, and the specifically targeting ABL myristoyl pocket (STAMP) inhibitor asciminib. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.